摘要
目的分析胸苷酸合成酶基因多态性对5-氟尿嘧啶临床疗效的影响。方法选取我院服用5-氟尿嘧啶进行治疗的50名食管癌患者,对患者胸苷酸合成酶进行基因分型,其中,将编码基因启动子区域包含两重串连28bp重复片断的纯合子基因型定义为S/S型,将编码基因启动子区域包含三重串连28bp重复片断的纯合子基因型定义为R/R型。杂合子基因型定义为R/S型。通过RT-PCR对mRNA含量进行相对定量。根据患者基因型测定结果,分析遗传学机制对5-氟尿嘧啶临床药物疗效的影响。结果50名患者中,发现R/R型患者20名,总有效率10%,R/S型患者22名,总有效率13.6%,S/S型患者8名,总有效率50%,R/R组与S/S比较以及R/S组与S/S组比较差异有统计学意义(P<0.05)。S/S型患者药物治疗平均生存时间20.3个月,较R/S组平均生存时间8.1个月以及R/R组平均生存时间7.9个月差异有统计学意义(P<0.05)。结论胸苷酸合成酶基因多态性是一个潜在的影响5-氟尿嘧啶的影响因素。
【Objective】To explore the influence of polymorphism of thymidylate synthetase on the clinical effect of 5-fluorouracil. 【Methods】The genotypes of thymidylate synthetase in 50 untreated esophageal cancer patients were analyzed. The homozygote with twice 28-bp tandem repeated sequence in promoter area was named as S/S,triple 28-bp tandem repeated sequence as R/R,the heterozygote with twice tandem repeated and triple tandem re-peated sequence as R/S. The mRNA level of thymidylate synthetase was detected by RT-PCR. The relationship be-tween the genotype of thymidylate synthetase and clinical effect of 5-fluorouracil was analyzed. 【Results】Among the 50 patients,there were 20 patients of R/R with 5-fluorouracil effect rate of 10%,22 patients of R/S with 5-fluo-rouracil effect rate of 13.6%,8 patients of S/S with 5-fluorouracil effect rate of 50%,the differences of the effect rate among the genotypes of R/R with S/S and R/S with S/S were significant (P <0.05). The mean survival time of the pa-tients of S/S was 20.3 months,which was significantly different from 8.1 months of R/S,and 7.9 months of S/S (P<0.05). 【Conclusion】The polymorphism of thymidylate synthetase is a potential factor that may influence the effect of 5-fluorouracil.
出处
《中国医学工程》
2008年第4期260-262,共3页
China Medical Engineering
